SCHEMBL379382

SCHEMBL379382

CCc1cc2ccc(Br)cc2nc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 4/20 0.46
GFER P55789 1/20 0.46
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
BACE1 P56817 2/20 0.42
GRM1 Q13255 1/20 0.38
HTT P42858 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 2/20 0.35
PSMB5 P28074 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
TERT O14746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31571092 1.00 KMT2A (0.50) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL667729 0.86 GRM1 (0.46) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL15449064 0.83 ALDH1A1 (0.60) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL15448379 0.82 ALDH1A1 (0.50) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL19243071 0.81 KMT2A (0.75) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL14047370 0.79 KMT2A (0.50) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL11982909 0.78 KMT2A (0.45) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL14846500 0.77 ALDH1A1 (0.54) KMT2ANPSR1ALDH1A1GFERKDM4E
SCHEMBL13166990 0.77 GRM1 (0.41) ALDH1A1GFERKDM4ECYP1A2CYP2C19
SCHEMBL3614209 0.77 BACE1 (0.46) KMT2ANPSR1ALDH1A1GFERKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020243178-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS ANGEX PHARMACEUTICAL, INC. (US) 2020-12-03 WO disclosed
US-8802671-B2 Quinoline derivatives as antibacterial agents JANSSEN PHARMACEUTICA NV (BE) 2014-08-12 US disclosed
US-8778966-B2 Quinolinone derivatives as PARP and tank inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-07-15 US disclosed
EP-2215075-B1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-12-11 EP disclosed
EP-1912648-B1 QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA NV (BE) 2013-04-10 EP disclosed
US-8404713-B2 Quinolinone derivatives as PARP inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-03-26 US disclosed
US-20130018017-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS VIALARD JORGE EDUARDO (BE) 2013-01-17 US disclosed
US-8299256-B2 Quinolinone derivatives as PARP and TANK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-10-30 US disclosed
EP-2134691-B1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-01-25 EP disclosed
CN-1910154-B Quinoline derivatives as mycobacterial inhibitors JANSSEN PHARMACEUTICA NV 2011-08-17 CN disclosed
EP-2134691-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2009-12-23 EP disclosed
WO-2009053373-A1 QUINOLINONE DERIVATIVES AS PARP INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-30 WO disclosed
CN-101277696-A Quinoline derivatives as antibacterial agents JANSSEN PHARMACEUTICA NV (BE) 2008-10-01 CN disclosed
WO-2008107478-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-09-12 WO disclosed
US-20080207687-A1 Quinoline Derivatives as Antibacterial Agents JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-28 US disclosed
EP-1713776-B1 QUINOLINE DERIVATIVES FOR USE AS MYCOBACTERIAL INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-05-14 EP disclosed
EP-1912648-A2 QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-23 EP disclosed
US-20070299106-A1 NOVEL MYCOBACTERIAL INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-12-27 US disclosed
WO-2007014941-A2 QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-02-08 WO disclosed
CN-1910154-A Quinoline derivatives as mycobacterial inhibitors JANSSEN PHARMACEUTICA NV (BE) 2007-02-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299106-A1 NOVEL MYCOBACTERIAL INHIBITORS NAT1, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 KMT2A 2927/4885NPSR1 1729/4885ALDH1A1 2080/4885
US-20080207687-A1 Quinoline Derivatives as Antibacterial Agents NQO2, QTRT1, RECQL KMT2A 3167/4885NPSR1 1459/4885ALDH1A1 2092/4885
US-20130018017-A1 QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS PARP1, PARP11, PARP3 KMT2A 495/4885NPSR1 2802/4885ALDH1A1 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.